Johnson & Johnson (NYSE:JNJ) Shares Sold by Hollow Brook Wealth Management LLC

Hollow Brook Wealth Management LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 0.4% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 49,055 shares of the company’s stock after selling 215 shares during the period. Johnson & Johnson comprises approximately 2.4% of Hollow Brook Wealth Management LLC’s investment portfolio, making the stock its 9th biggest holding. Hollow Brook Wealth Management LLC’s holdings in Johnson & Johnson were worth $7,950,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in JNJ. Holocene Advisors LP bought a new position in shares of Johnson & Johnson in the third quarter valued at about $225,040,000. Cladis Investment Advisory LLC increased its stake in Johnson & Johnson by 3.0% during the 3rd quarter. Cladis Investment Advisory LLC now owns 4,354 shares of the company’s stock worth $706,000 after acquiring an additional 125 shares during the period. Coastwise Capital Group LLC lifted its position in shares of Johnson & Johnson by 20.8% during the 3rd quarter. Coastwise Capital Group LLC now owns 6,402 shares of the company’s stock valued at $1,037,000 after acquiring an additional 1,103 shares during the period. Community Bank N.A. raised its stake in Johnson & Johnson by 1.0% in the third quarter. Community Bank N.A. now owns 43,480 shares of the company’s stock valued at $7,046,000 after purchasing an additional 410 shares in the last quarter. Finally, Concentric Capital Strategies LP increased its position in Johnson & Johnson by 66.5% during the 3rd quarter. Concentric Capital Strategies LP now owns 10,058 shares of the company’s stock worth $1,630,000 after purchasing an additional 4,016 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

NYSE JNJ opened at $154.82 on Monday. The company has a market cap of $372.75 billion, a PE ratio of 22.43, a price-to-earnings-growth ratio of 2.75 and a beta of 0.53. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm’s 50-day simple moving average is $159.15 and its two-hundred day simple moving average is $156.46. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.66 EPS. Research analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.20%. Johnson & Johnson’s payout ratio is presently 71.78%.

Analysts Set New Price Targets

JNJ has been the subject of several research analyst reports. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Guggenheim upped their target price on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Morgan Stanley upped their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Seven investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $175.67.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.